Media about us
-
Russia – USA. The bilateral business interest in investment remains high.
29 May 2017
In their first talks, Russia’s President Vladimir Putin and the US President Donald Trump noted the importance of restoring full-scale economic partnership, with due account of the fact that in 2016 Russian-American projects started and continued virtually across the entire economy. The numbers include the US investments in Russian export-oriented and import-substituting industries. A number of such projects began in 2016 alone, with Pfizer’s pharmaceutical factory and Novamedica Company in the Kaluga Region among them.
-
US Companies in Russia Regularly Confirm Determination to Stay - Embassy
29 May 2017
Minister-Counselor of the Russian Embassy in the United States Denis Gonchar said in anterview with Sputnik on Monday that American companies working in Russia regularly confirm that they are not going to leave the country. One of his examples that US global pharmaceutical corporation Pfizer and Russian pharmaceutical company NovaMedica signed a strategic partnership agreement, including the construction of a manufacturing plant in the Vorsino industrial park for production of more than 30 vital medicinal products and the work of joint technical laboratories in Moscow.
-
Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
17 May 2017
Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.
-
Epic Sciences nets $40M for cancer liquid biopsy
02 May 2017
Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.
-
Biopharma just can’t get enough of Epic Sciences
02 May 2017
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.
-
With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer
02 May 2017
When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.
-
Corneal inlays need your boost to hit their stride
10 April 2017
Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.
-
New help for that bane of middle-age: blurry close-up vision
07 March 2017
Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?
-
Atlas to invest in extra capacity at STI test manufacturing partner Bespak
16 February 2017
Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.
-
Liquid biopsies: The next frontier in cancer?
15 February 2017
As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.
